CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Tarsus Pharmaceuticals, Inc. - TARS CFD

    16.53
    1.67%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Tarsus Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 16.81
    Open* 16.57
    1-Year Change* -2.07%
    Day's Range* 16.53 - 16.76
    52 wk Range 11.33-25.25
    Average Volume (10 days) 780.26K
    Average Volume (3 months) 10.40M
    Market Cap 581.65M
    P/E Ratio -100.00K
    Shares Outstanding 33.10M
    Revenue 14.37M
    EPS -3.84
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Mar 11, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 28, 2023 16.53 -0.04 -0.24% 16.57 16.79 16.52
    Nov 27, 2023 16.81 -0.48 -2.78% 17.29 17.35 16.67
    Nov 24, 2023 17.15 0.18 1.06% 16.97 17.94 16.97
    Nov 22, 2023 17.51 -0.27 -1.52% 17.78 17.78 17.24
    Nov 21, 2023 17.53 0.27 1.56% 17.26 17.79 16.87
    Nov 20, 2023 17.46 -0.53 -2.95% 17.99 18.68 17.45
    Nov 17, 2023 18.82 1.14 6.45% 17.68 18.83 17.10
    Nov 16, 2023 17.69 -0.21 -1.17% 17.90 18.05 17.27
    Nov 15, 2023 17.88 1.11 6.62% 16.77 19.26 16.77
    Nov 14, 2023 17.87 0.90 5.30% 16.97 17.92 16.47
    Nov 13, 2023 17.11 0.29 1.72% 16.82 17.58 16.47
    Nov 10, 2023 17.44 0.94 5.70% 16.50 18.07 16.50
    Nov 9, 2023 15.50 -0.38 -2.39% 15.88 16.43 15.42
    Nov 8, 2023 16.51 1.02 6.58% 15.49 16.60 15.49
    Nov 7, 2023 16.04 0.25 1.58% 15.79 16.19 15.65
    Nov 6, 2023 15.95 0.22 1.40% 15.73 16.23 15.73
    Nov 3, 2023 15.98 1.36 9.30% 14.62 16.19 14.62
    Nov 2, 2023 14.60 0.45 3.18% 14.15 14.88 14.15
    Nov 1, 2023 14.48 0.69 5.00% 13.79 14.48 13.62
    Oct 31, 2023 14.22 0.23 1.64% 13.99 14.27 13.77

    Tarsus Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Monday, March 11, 2024

    Time (UTC)

    20:05

    Country

    US

    Event

    Q4 2023 Tarsus Pharmaceuticals Inc Earnings Release
    Q4 2023 Tarsus Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 25.816 57.027 0 0 0
    Total Operating Expense 88.528 69.184 26.998 4.553 1.35
    Selling/General/Admin. Expenses, Total 44.949 25.397 8.172 1.136 0.449
    Research & Development 42.624 41.712 18.826 3.162 0.901
    Unusual Expense (Income) 0 0.255 0
    Operating Income -62.712 -12.157 -26.998 -4.553 -1.35
    Interest Income (Expense), Net Non-Operating 0.531 -1.542 0.188 -0.116 0.032
    Net Income Before Taxes -62.095 -13.772 -26.81 -4.669 -1.318
    Net Income After Taxes -62.091 -13.827 -26.811 -4.67 -1.319
    Net Income Before Extra. Items -62.091 -13.827 -26.811 -4.67 -1.319
    Net Income -62.091 -13.827 -26.811 -4.67 -1.319
    Income Available to Common Excl. Extra. Items -62.091 -13.827 -26.811 -4.67 -1.319
    Income Available to Common Incl. Extra. Items -62.091 -13.827 -26.811 -4.67 -1.319
    Diluted Net Income -62.091 -13.827 -26.811 -4.67 -1.319
    Diluted Weighted Average Shares 24.6197 20.5541 20.5031 18.759 18.759
    Diluted EPS Excluding Extraordinary Items -2.522 -0.67271 -1.30766 -0.24895 -0.07031
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -2.522 -0.67271 -1.30766 -0.24011 -0.07031
    Revenue 25.816 57.027
    Cost of Revenue, Total 0.955 2.075
    Gross Profit 24.861 54.952
    Other, Net 0.086 -0.073
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 2.5 10 0 15.277
    Revenue 0 2.5 10 0 15.277
    Cost of Revenue, Total 0 0 0.4 0 0.522
    Gross Profit 0 2.5 9.6 0 14.755
    Total Operating Expense 32.821 27.452 25.061 22.906 20.501
    Selling/General/Admin. Expenses, Total 20.275 15.096 14.633 11.994 10.376
    Research & Development 12.546 12.356 10.028 10.912 9.603
    Operating Income -32.821 -24.952 -15.061 -22.906 -5.224
    Interest Income (Expense), Net Non-Operating 1.444 1.527 1.512 0.397 -0.625
    Other, Net -0.047 0.006 -0.05 -0.007 0.106
    Net Income Before Taxes -31.424 -23.419 -13.599 -22.516 -5.743
    Net Income After Taxes -31.424 -23.419 -13.599 -22.511 -5.743
    Net Income Before Extra. Items -31.424 -23.419 -13.599 -22.511 -5.743
    Net Income -31.424 -23.419 -13.599 -22.511 -5.743
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -31.424 -23.419 -13.599 -22.511 -5.743
    Income Available to Common Incl. Extra. Items -31.424 -23.419 -13.599 -22.511 -5.743
    Dilution Adjustment
    Diluted Net Income -31.424 -23.419 -13.599 -22.511 -5.743
    Diluted Weighted Average Shares 26.8157 26.742 26.7083 26.6624 24.3325
    Diluted EPS Excluding Extraordinary Items -1.17185 -0.87574 -0.50917 -0.8443 -0.23602
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -1.17185 -0.87574 -0.50917 -0.8443 -0.23602
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 225.375 175.952 170.655 58.03 2.383
    Cash and Short Term Investments 217.026 171.815 168.129 57.952 2.355
    Cash & Equivalents 71.66 171.332 168.129 57.952 2.355
    Total Receivables, Net 3.582 0.092 0.02 0.036 0.004
    Prepaid Expenses 4.767 4.045 2.486 0.022 0.004
    Other Current Assets, Total 0 0.02 0.02 0.02
    Total Assets 227.863 178.907 171.972 58.316 2.389
    Property/Plant/Equipment, Total - Net 1.532 1.829 1.236 0.28 0.006
    Property/Plant/Equipment, Total - Gross 2.078 2.05 1.37 0.318 0.007
    Accumulated Depreciation, Total -0.546 -0.221 -0.134 -0.038 -0.001
    Other Long Term Assets, Total 0.585 1.126 0.081 0.006 0
    Total Current Liabilities 15.429 11.478 5.387 0.819 0.179
    Accounts Payable 5.269 2.856 2.237 0.456 0.175
    Accrued Expenses 10.146 7.87 3.15 0.363 0.004
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 34.963 12.177 5.992 0.919 0.179
    Total Long Term Debt 19.434 0 0 0 0
    Other Liabilities, Total 0.1 0.699 0.605 0.1 0
    Total Equity 192.9 166.73 165.98 57.397 2.21
    Preferred Stock - Non Redeemable, Net 0 0 63.402 3.564
    Common Stock 0.005 0.004 0.004 0.002 0.001
    Additional Paid-In Capital 301.732 213.398 198.821 0.027 0.009
    Retained Earnings (Accumulated Deficit) -108.763 -46.672 -32.845 -6.034 -1.364
    Total Liabilities & Shareholders’ Equity 227.863 178.907 171.972 58.316 2.389
    Total Common Shares Outstanding 26.7275 20.7266 20.5031 18.759 18.759
    Short Term Investments 145.366 0.483
    Other Current Liabilities, Total 0.014 0.752
    Long Term Investments 0.371
    Long Term Debt 19.434
    Other Equity, Total -0.074
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 259.277 183.476 208.646 225.375 234.078
    Cash and Short Term Investments 246.885 178.228 201.219 217.026 226.572
    Cash & Equivalents 226.672 106.773 65.997 71.66 169.489
    Total Receivables, Net 6.37 0.246 2.918 3.582 4.012
    Accounts Receivable - Trade, Net 5.362 2.5 0.017
    Prepaid Expenses 6.007 5.002 4.509 4.767 3.494
    Other Current Assets, Total
    Total Assets 268.332 188.927 211.214 227.863 236.465
    Property/Plant/Equipment, Total - Net 3.625 3.678 1.733 1.532 1.647
    Property/Plant/Equipment, Total - Gross 4.667 4.51 2.382 2.078 2.095
    Accumulated Depreciation, Total -1.042 -0.832 -0.649 -0.546 -0.448
    Other Long Term Assets, Total 1.253 1.451 0.529 0.585 0.583
    Total Current Liabilities 23.249 14.765 13.255 15.429 14.273
    Accounts Payable 10.382 8.172 7.566 5.269 5.592
    Accrued Expenses 12.867 6.593 5.675 10.146 8.667
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.014 0.014 0.014
    Total Liabilities 54.668 41.198 37.81 34.963 33.838
    Total Long Term Debt 29.708 24.607 24.515 19.434 19.356
    Other Liabilities, Total 1.711 1.826 0.04 0.1 0.209
    Total Equity 213.664 147.729 173.404 192.9 202.627
    Common Stock 0.005 0.005 0.005 0.005 0.005
    Additional Paid-In Capital 416.421 311.353 305.651 301.732 297.796
    Retained Earnings (Accumulated Deficit) -202.754 -163.606 -132.182 -108.763 -95.164
    Total Liabilities & Shareholders’ Equity 268.332 188.927 211.214 227.863 236.465
    Total Common Shares Outstanding 33.1041 26.8996 26.8005 26.7275 26.6718
    Short Term Investments 20.213 71.455 135.222 145.366 57.083
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Long Term Debt 29.708 24.607 24.515 19.434 19.356
    Long Term Investments 0.21 0.322 0.306 0.371 0.157
    Other Equity, Total -0.008 -0.023 -0.07 -0.074 -0.01
    Total Inventory 0.015
    Intangibles, Net 3.967
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -62.091 -13.827 -26.811 -4.67 -1.319
    Cash From Operating Activities -49.03 3.748 -21.138 -3.673 -1.183
    Cash From Operating Activities 0.325 0.312 0.096 0.037 0.001
    Non-Cash Items 13.687 15.891 4.119 0.475 0.009
    Changes in Working Capital -0.951 1.372 1.458 0.485 0.126
    Cash From Investing Activities -144.629 -0.586 -0.456 -0.175 -0.007
    Capital Expenditures -0.506 -0.586 -0.456 -0.175 -0.007
    Cash From Financing Activities 93.987 0.021 131.771 59.445 3.564
    Issuance (Retirement) of Stock, Net 74.937 0.324 40.098 57.456 3.564
    Issuance (Retirement) of Debt, Net 20 0 1.989 0
    Net Change in Cash -99.672 3.183 110.177 55.597 2.374
    Financing Cash Flow Items -0.95 -0.303 91.673
    Cash Interest Paid 1.675
    Other Investing Cash Flow Items, Total -144.123
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -23.419 -62.091 -48.492 -25.981 -20.238
    Cash From Operating Activities -21.97 -49.03 -38.156 -19.545 -15.286
    Cash From Operating Activities 0.104 0.325 0.227 0.133 0.041
    Non-Cash Items 2.752 13.687 11.145 7.383 3.28
    Changes in Working Capital -1.407 -0.951 -1.036 -1.08 1.631
    Cash From Investing Activities 11.294 -144.629 -57.41 -0.283 -0.161
    Capital Expenditures -0.34 -0.506 -0.379 -0.283 -0.161
    Cash From Financing Activities 5.013 93.987 93.723 93.859 19.125
    Issuance (Retirement) of Stock, Net 0.013 74.937 74.673 74.809 0
    Net Change in Cash -5.663 -99.672 -1.843 74.031 3.678
    Financing Cash Flow Items 0 -0.95 -0.95 -0.95 -0.875
    Cash Interest Paid 0.593 1.675 1.094 0.127 0.127
    Issuance (Retirement) of Debt, Net 5 20 20 20 20
    Other Investing Cash Flow Items, Total 11.634 -144.123 -57.031
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    RTW Investments L.P. Investment Advisor/Hedge Fund 7.8124 2548125 0 2023-06-30 LOW
    Vivo Capital, LLC Venture Capital 6.9357 2262200 0 2023-06-30 LOW
    Cowen & Co., LLC Research Firm 6.13 1999383 600400 2023-06-30 MED
    Frazier Healthcare Partners Venture Capital 5.4804 1787527 0 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.464 1782174 555683 2023-06-30 LOW
    Tang Capital Management, LLC Hedge Fund 5.4548 1779158 -255000 2023-06-30 MED
    Cormorant Asset Management, LP Hedge Fund 4.358 1421422 0 2023-06-30 LOW
    Perceptive Advisors LLC Private Equity 3.9747 1296416 0 2023-06-30 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.7662 1228410 10133 2023-06-30 LOW
    Ackermann (Michael) Individual Investor 3.7045 1208273 4257 2022-06-15
    Azamian (Bobak R) Individual Investor 3.3392 1089133 -116723 2023-03-31
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3639 444861 95712 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.2899 420716 56421 2023-06-30 LOW
    Jefferies LLC Research Firm 1.0907 355758 -90000 2023-06-30 HIGH
    Sands Capital Ventures LLC Hedge Fund 0.7971 260000 0 2023-06-30 MED
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.7863 256460 20930 2023-06-30 LOW
    Allspring Global Investments, LLC Investment Advisor/Hedge Fund 0.7541 245972 237445 2023-09-30 LOW
    Artisan Partners Limited Partnership Investment Advisor 0.7541 245969 245969 2023-09-30 LOW
    Ensign Peak Advisors, Inc. Foundation 0.7433 242451 0 2023-06-30 LOW
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.6988 227937 131608 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Tarsus Pharmaceuticals, Inc. Company profile

    About Tarsus Pharmaceuticals Inc

    Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The Company is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Tarsus Pharmaceuticals Inc revenues increased from $0K to $56.7M. Net income applicable to common stockholders totaled $1M vs. loss of $15.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to $0.05.

    Industry: Pharmaceuticals (NEC)

    15440 Laguna Canyon Road
    IRVINE
    CALIFORNIA 92618
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023

    People also watch

    Gold

    2,043.71 Price
    +0.050% 1D Chg, %
    Long position overnight fee -0.0191%
    Short position overnight fee 0.0109%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    BTC/USD

    38,210.80 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    XRP/USD

    0.62 Price
    +0.130% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    16,039.00 Price
    +0.090% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading